Clinical trials leading to drug approvals for various blood cancers have significantly underrepresented Blacks and minorities, leading to questions about the generalizability of safety and efficacy, say experts.
Medscape Medical News
Pivotal Trials in Blood Cancers Don’t Mirror Patient Populations
